Radiation therapy for colorectal cancer
Doctors use different types of radiation therapy to treat both rectal and colon cancer. Being treated with chemotherapy at the same time can make radiation therapy more effective for some colorectal cancers.
Doctors use different types of radiation therapy to treat both rectal and colon cancer. Being treated with chemotherapy at the same time can make radiation therapy more effective for some colorectal cancers.
Radiation therapy is a form of cancer treatment that uses high-energy rays to destroy cancer cells. The cells in your body normally grow and divide to form new cells. Cancer cells grow and divide faster than normal cells, which can create tumors. Radiation damages the DNA inside cells. When the cells are damaged, they stop growing and dividing and eventually die.
Radiation therapy is a common treatment for rectal cancer. It is used either before or after surgery, and usually along with chemotherapy.
It may be used prior to surgery (neoadjuvant therapy) to shrink a tumor to make it easier to remove, or afterwards to destroy cancer cells that cannot be removed with surgery.
Rectal tumors that come back in the pelvis after radiation therapy may be re-treated with radiation.
Radiation therapy may also be used to ease symptoms of advanced rectal cancer such as pain, bleeding, or intestinal obstructions.
Talk with your doctor about the possible side effects of your radiation therapy regimen before your treatment begins so you know what to expect. Most side effects go away soon after treatment is finished, but some may not go away completely. Ask your doctor about any lasting side effects.
Possible side effects from radiation therapy for colorectal cancer may include:
If you are planning to have a child, talk to your doctor before treatment begins about your options for preserving fertility.
Michelle Cappel owes a lot to colorectal cancer biomarker testing — seven years of life and counting.
Don Shippey was 55 years old in 2016 when he decided he’d been putting off his colonoscopy long enough.
Takeda has announced U.S. Food and Drug Administration (FDA) approval of FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.